An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Project Information in NIH RePORTER
An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children
Principal Institution
Global Health Uganda, LTD
Principal Investigator(s) (PI)
Opoka, Robert; Rollins, Angela Leigh
Project Contact Information
Email:
admin@globalhealthuganda.org
Year(s) Awarded
2021-2023
Country
Uganda
Project Description
This study will use a broad implementation framework to develop a set of implementation supports for scaling up hydroxyurea use that can be used in a larger implementation trial while also simultaneously preparing for the capacity building phase required in ongoing implementation. In the short-term, achieving these study aims will support the Ugandan Ministry of Health in establishing widespread use of hydroxyurea for children with sickle cell disease and prepare for a larger, multisite implementation- effectiveness trial by developing an informed implementation approach with a high likelihood of success.
Our project is innovative in that it centers around regional and district pilot sites that are often omitted in large effectiveness studies but provide a substantial portion of care in Africa. Over the long-term, given the high prevalence of sickle cell disease in sub-Saharan Africa, improving access to the safe and effective use of hydroxyurea could substantially improve mortality and suffering amongst the many children with sickle cell disease.
Related World Regions / Countries